Abstract
The 'true' incidence of spontaneous regression of neuroblastomas is uncertain. However, the frequency of spontaneous regression is important when the benefits of screening procedures are considered. In the population-based Danish neuroblastoma survey 1943-80, spontaneous regression was documented in less than 2% of cases. However, the 'true' incidence may be higher. The epidemiological findings of increased incidence and survival rates with an unchanged mortality rate may suggest the inclusion of borderline lesions among 'truly' malignant neuroblastomas in recent decades in Denmark. However, it is more likely to be a result of improved diagnosis, changes in the social composition of the population and possibly unidentified environmental agents. However, if some premalignant lesions in fact had been included, they are most likely to be stages I-II tumours of infancy. In this study we describe cases of spontaneous regression of neuroblastoma from the Danish population-based survey 1943-80.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry
Analytical and Bioanalytical Chemistry Open Access 25 June 2018
-
Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study
British Journal of Cancer Open Access 17 February 2009
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carlsen, N. How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer 61, 441–446 (1990). https://doi.org/10.1038/bjc.1990.97
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.97
This article is cited by
-
MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective
Virchows Archiv (2023)
-
Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry
Analytical and Bioanalytical Chemistry (2018)
-
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Nature Reviews Clinical Oncology (2012)
-
Development of treatment strategies for advanced neuroblastoma
International Journal of Clinical Oncology (2012)
-
Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study
British Journal of Cancer (2009)